Fibrocell Science, Inc.’s LAVIV™ (azficel-T) Available to Adult Women Searching for the Latest Beauty Breakthrough

From New York to Los Angeles and Miami, Fibrocell Science, Inc.’s

(OTCBB:FCSC) LAVIV™ (azficel-T) has been making headlines as one of the

latest treatments to hit the aesthetics market. Latinas place great

importance on appearance – 69 percent report that wearing makeup and

looking good is essential versus 46 percent of non-Latinas, according to

a 2011 Univision study. Now with LAVIV, a customized injectable

treatment, Latina adults with moderate to severe smile line (nasolabial

fold) wrinkles can improve the look of these wrinkles by using their own

living, cultured, collagen-producing fibroblast cells.

“Hispanic women are known for being early adopters of ground-breaking

beauty and personal care treatments,” said Julio M. Gallo, MD, FACS,

medical director and facial plastic surgeon at The MIAMI Institute for

Age Management in Miami. “I believe LAVIV is a cutting edge

treatment that Latinas across the country should know about. It

helps

improve a patient’s outer beauty from within using state of the art

technology to treat smile line wrinkles in a very customized way. I

don’t think there’s anything quite like it on the market.”

The patented technology behind LAVIV is an advanced process that

extracts a person’s fibroblast cells from a small skin sample taken from

behind the ear and multiplies them in the Fibrocell Science lab. In

normal skin, fibroblasts are responsible for producing collagen, which

gives skin its tone and structure. LAVIV is the resulting

formulation of a person’s own living, cultured fibroblast cells, which

is then injected into moderate to severe smile lines. Each person’s

formulation of LAVIV is unique because it is made from their own

cells.

According to the American Society for Aesthetic Plastic Surgery,

Hispanics lead all minority groups in cosmetic surgery, and there has

been a 49 percent increase in procedures among Hispanics since 2000. In

2009, about 1.4 million Latinos underwent cosmetic procedures, from

surgery to injections; a threefold increase from nine years earlier,

according to the American Society of Plastic Surgeons.

For more information on LAVIV, including Contraindications,

Warnings and Precautions and Adverse Reactions, please see the

accompanying full Prescribing Information. To find a certified physician

in your area, please visit www.mylaviv.com.

LAVIV™ (azficel-T) is an autologous cellular product indicated

for improvement of the appearance of moderate to severe nasolabial fold

wrinkles in adults. The safety and efficacy of LAVIV for areas

other than nasolabial folds have not been established. The efficacy of LAVIV

beyond six months has not been established.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV is made especially for you from your own skin cells. Using

someone else’s cells can cause a serious reaction. Do not let anyone

else use your LAVIV. Prior to injection, confirm with your

physician that your information on the LAVIV vial is correct.

Your health care provider will help you to decide whether you are a

candidate for LAVIV and may help you avoid some of the adverse

reactions from LAVIV. Before getting LAVIV, tell your

healthcare provider if you have any medical problems including allergic

reactions to any drugs or food, bleeding disorders or take

blood-thinning medicines like aspirin, ibuprofen, or Coumadin® (warfarin

sodium), keloids or excessive scarring, skin cancer or any malignancy,

genetic disorders affecting your skin, immune problems or take medicines

that affect your immune system, or any other illness or medical problem.

Please tell your healthcare provider if you are allergic to the

antibiotics amphotericin or gentamicin, bovine materials (products made

from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if

you have a skin infection on your face because LAVIV treatment

can make the infection worse.

The most common side effects of LAVIV are at the injection-site,

including redness, bruising, swelling, pain, bleeding, lumps,

irritation, and itchiness. In clinical trials with LAVIV, most

injection-site adverse reactions resolved within one week and most

required no treatment. The full Prescribing Information for LAVIV

includes additional warnings about adverse reactions that occurred in

less than 1% of patients following LAVIV treatment in clinical trials.

Talk to your healthcare provider about these warnings.

Only healthcare providers who have completed a Fibrocell-approved

training program should administer LAVIV.

Please see the full Prescribing Information for LAVIV Contraindications,

Warnings, Precautions and Adverse Reactions at www.mylaviv.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB:FCSC.OB) is a cell therapy company

focused on the development of autologous (personalized) cell therapies

for aesthetic, medical and scientific applications. Fibrocell Science is

committed to advancing the scientific, medical and commercial potential

of autologous skin and tissue, as well as its innovative cellular

processing technology and manufacturing excellence. For additional

information, please visit www.fibrocellscience.com.